Physician profile
Mark E Johns
NPI 1558350579
$1,938.90
in general payments reported to CMS, 2019-2025
24 companies · $287 in 2025
The $287 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $66.64 · 2021: $203 · 2022: $358 · 2023: $438 · 2024: $393 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $256.52 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $250.37 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.18 | 2021-2024 | |
| Irhythm Technologies, INC. | $147.43 | 2019-2023 | Zio Xt Patch |
| Baxter Healthcare | $133.95 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Pfizer INC. | $123.76 | 2023-2025 | |
| Amgen INC. | $121.28 | 2021-2025 | Repatha, Repatha |
| Akcea Therapeutics, INC. | $120.83 | 2019 | |
| Boston Scientific Corporation | $87.45 | 2025 | Cds - Mct/Cem Monitoring, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $78.91 | 2019-2024 | Eliquis, Camzyos |
| Edwards Lifesciences Corporation | $70.13 | 2020-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medicomp INC | $54.31 | 2023-2024 | Telepatch Cardiac Monitor |
| Impulse Dynamics (USA) INC. | $42.11 | 2023 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $41.50 | 2024-2025 | |
| Esperion Therapeutics, INC. | $38.08 | 2023-2024 | Nexletol |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $36.54 | 2023-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $32.94 | 2022-2025 | Lokelma |
| Scpharmaceuticals INC. | $30.83 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $22.98 | 2024 | Arcalyst |
| Vifor Pharma, INC. | $21.09 | 2021 | |
| Bridgebio Pharma, INC. | $19.77 | 2025 | Attruby |
| Merck Sharp & Dohme LLC | $18.74 | 2025 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $17.12 | 2023 | Evkeeza |
| Philips North America LLC | $17.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Johns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.